Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
LUCY 10-Q must be due, last one was the 11th August.
The NASDAQ non-compliance notice was issued on the 4th August. They've 180 days from then for the price to be above $1, for 30 consecutive days.
Without better numbers they'll be dangerously close to delisting next year, before Reebok, Eddie Bauer and Nautica even come on stream.
If the quarterly revenue numbers are weak then Harrison Gross has to be replaced.
Fake news (again),
The EUDA website has been down since the weekend. 264 shares traded (on ii) and I can buy @$1.44.
You're all bonkers.
Do us a favour Gunner, sell up!
"A jolly"?
Do you want the directors to sit in a Pampisford office waiting for the Golden Goose to come knocking?
"Save their necks".
Do you think they sat about waiting for the MHRA? No, they took the bull by the horns and went to Oz.
I can read your broken record reply already....."12 years and nothing, moan, moan, moan"....ad infinitum.
Exactly fella,
I can't wait for "deal" or "no deal" day.
Hopefully we'll have clinical trials, evaluations and scientific partnerships to discuss - for a change!👍
Or maybe a placing...🫣
Good luck!!
Wayne,
We've not had news because I'd guess it all hinges on the cash for VAL201.
It'll be the catalyst for some big moves at Valirx.
Hang in there!!
👍
ADASTEC already run a 3.73 mile Level 4 route in Stavanger for an automated bus service.
I guess they need Guident for human intervention to help passengers with mobility issues.
That's how I read it.
Excellent news.
Nice find Mr Rozzy,
Can you provide a link? I'd be very interested to read about it.
ADASTEC provide automated bus tech (amongst other things).
👍
Source: taken directly from the Telegram group, posted by Harrison Gross;
"All as you know I have a limitations on what I can say and it must be public information. Here is a brief update for our community giving as much information as possible.
Software
We are making good progress on the apps front, as you may be aware we launched the first ever voice interface for ChatGPT in April, making our glasses the first with access to this powerful AI. The Lucyd app has been well received by users and provides free access to the paid version of ChatGPT. A massive 2.0 update just launched for iOS with additional AI tools and significant interface upgrades, the Android 2.0 version is coming in 2 weeks.
More features are planned for the Lucyd app and the tokenization plans for the Vyrb app are still underway. This has been delayed by a variety of factors related to the glasses and resource allotments, but is still underway and a committed part of our roadmap.
We have also hired a full time IOS engineer to support our CTO Eric and continue to build our software ecosystem more rapidly than before - we anticipate hiring a full time Android engineer as well in the near future. We also leverage several external developer teams to have some extra support in software development.
If you’ve downloaded Vyrb you’ve seen that we have put together a lot of really useful creator tools in one place - livestreaming audio, traditional social media elements, importing audio and light audio editing capabilities. More to come here as we aim to make Vyrb the ideal platform for free expression, control of your content and monetization of content.
Glasses
The new Lucyd Lyte XL frames launched last week, they are our most advanced glasses ever and I would be glad to get some out to our community here for some tokens. This product is clear evidence of our long-term commitment to revolutionizing smart eyewear and boasts our new patent-pending flexible hinges, thinnest temples yet and best sound quality yet by miles. These glasses are really a design achievement and are built on 5+ years of smartglass R&D.
Nautica powered by Lucyd, Eddie Bauer powered by Lucyd, and Reebok powered by Lucyd collections are all coming in the next six months and will likely raise the profile of our company significantly.
So in essence we are well on our way to realizing the mission of the Lucyd whitepaper: we are creating revolutionary smart eyewear products and a peer-to-peer content economy for smart eyewear, via the Vyrb app. So much infrastructure and technology has been developed towards this ultimate goal, and the vision remains the same: a future where people create, share and enjoy content on their glasses."
A very comprehensive offering, although you have to apply via an authorised third party to get Medicare or Medicaid.
They've got a chatbot with a $500 sale offer already!
I expect Lolly will be along shortly to dampen our enthusiasm. 😀
Indeed Sea,
Buy, lease or rent - prescription required. Plenty of add-ons to boost the profit such as accessories, warranties, finance and spare cartridges.
https://xploroxygen.com/product/discov-r/
Unfortunately no numbers of units sold, from the direct to consumer test.
We disagree Lolly,
In my view, it's wrong to suggest that TEK's "business model is broken".
BELL have a FDA authorised product, large contracts with McKesson and Innomax and HNWI investor backing.
I don't see that as failure, I see it as an investment opportunity.
I guess that's where we differ, glass half full and all that.
Good luck with your strategy. 👍
Gotta disagree chaps,
Cliff's a wily operator, he's been here before at sub 10p.
I guarantee he'll pull an RNS out of the bag to boost the SP, before any raise.
My guess would be AI related, given the recent developments in the Half Year report. Although, with five portfolio companies, there are plenty of opportunities for good news.
Indeed Veteran,
BELL merger is nearing completion, with funds to fulfil contracts and HNWI's backing the CLN's.
Lucy up 12.69% too.
Microsalt could be delayed for financial, technical or legal reasons.
I grabbed a couple of grands worth last night at 9p and 9.2p.
Be greedy when others are fearful, eh?
Https://www.theguardian.com/society/2023/oct/16/new-prostate-cancer-treatment-may-be-on-the-horizon-say-scientists
"They were given a combination of AZD5069, an experimental drug that prevents white blood cells from being dragged inside tumours, and enzalutamide, a hormone therapy commonly used to treat prostate cancer.
Of 21 patients who could be evaluated, five (24%) showed evidence of their tumours responding to the combination, the ICR reported.
Their tumours shrunk by more than 30%, they experienced “dramatic decreases” in circulating levels of prostate specific antigen (PSA), a marker often elevated by cancer, or their blood levels of circulating tumour cells dropped, it said."
I belive VAL201 had better results, albeit in a smaller cohort of patients.
Looks like they've adjusted the benefit to 40% salt reduction.
(I'm certain it was previously 50%).
For non-subscribers;
"Under pressure from the health ministry, the salt content in the city’s baguettes was cut from 1.5g per 100g of bread to 1.4g. It seems that the morning baguette currently accounts for 18% of the average French adult’s salt intake of 7.7g a day, which is somewhat distant from the World Health Organization’s recommended 5g, and so – zut, alors! – things had to change. Needless to say, some people are unhappy about this. Bakers, who have already cut the salt content of their baguettes (by 20% since 2015), believe the taste of the bread may suffer, and so do some customers. The word “insipid” has been uttered."
Https://www.theguardian.com/food/2023/oct/14/the-french-are-having-a-tiff-about-salt-in-baguettes-and-i-totally-understand-why
Anyone know of a solution?
Indeed Baf,
Lolly persists with a Soda-Lo comparison, a discontinued product that reduced daily salt intake by around 10%.
Microsalt is real salt and hits 50% sodium reduction without compromising taste. It adheres like salt and they've orders for multiple applications in the food industry.
It's beyond me as to why Lolly persists with history lessons unless, as you point out, he is a shorter.
Lolly,
Your investment analysis consists entirely of history lessons, hindsight (a wonderful thing) and the use of a discarded, poor quality comparison product from four years ago. Don't you even consider that BELL (the first to float) has now secured contracts and a royalty agreement in a major jurisdiction (China), therefore has enormous potential?
I've suggested LUCY needs a CEO change and that they should be focused on sales instead of endless product developments. Given that, they still have agreements with Nautica and Reebok lined up for 2024.
Microsalt have issued a prospectus detailing corporate interest in the product and the requirement for a manufacturing facility.
Does your investment strategy ever consider future potential, or is your entire rationale an "I told you so" style of research?
(Apologies - I mean 10-Q, obviously!).